- Home
- USB vs REGN Comparison
USB vs REGN Comparison
Compare USB & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USB
- REGN
- Stock Information
- Founded
- USB 1863
- REGN 1988
- Country
- USB United States
- REGN United States
- Employees
- USB N/A
- REGN N/A
- Industry
- USB Major Banks
- REGN Biotechnology: Pharmaceutical Preparations
- Sector
- USB Finance
- REGN Health Care
- Exchange
- USB Nasdaq
- REGN Nasdaq
- Market Cap
- USB 62.9B
- REGN 63.4B
- IPO Year
- USB N/A
- REGN 1991
- Fundamental
- Price
- USB $42.04
- REGN $537.97
- Analyst Decision
- USB Buy
- REGN Buy
- Analyst Count
- USB 21
- REGN 23
- Target Price
- USB $50.31
- REGN $907.39
- AVG Volume (30 Days)
- USB 10.3M
- REGN 1.2M
- Earning Date
- USB 04-16-2025
- REGN 04-29-2025
- Dividend Yield
- USB 4.75%
- REGN 0.32%
- EPS Growth
- USB 34.12
- REGN 16.49
- EPS
- USB 4.04
- REGN 39.43
- Revenue
- USB $25,356,000,000.00
- REGN $14,085,700,000.00
- Revenue This Year
- USB $14.48
- REGN $2.38
- Revenue Next Year
- USB $4.43
- REGN $7.65
- P/E Ratio
- USB $10.43
- REGN $14.23
- Revenue Growth
- USB 0.80
- REGN 7.52
- 52 Week Low
- USB $35.18
- REGN $520.50
- 52 Week High
- USB $53.98
- REGN $1,211.20
- Technical
- Relative Strength Index (RSI)
- USB 59.99
- REGN 38.73
- Support Level
- USB $40.89
- REGN $520.50
- Resistance Level
- USB $42.35
- REGN $615.61
- Average True Range (ATR)
- USB 0.84
- REGN 21.38
- MACD
- USB 0.43
- REGN -1.27
- Stochastic Oscillator
- USB 94.51
- REGN 28.67
About USB U.S. Bancorp
With assets of around $680 billion, U.S. Bancorp is one of the largest regional banks in the US with its footprint in 26 states. The bank's branch network is mostly in midwestern and western markets. U.S. Bancorp has a comprehensive product set, with offerings in retail and commercial banking, credit cards, mortgages, payment services, trust, and wealth services.
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals Inc discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).